Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Akoya Biosciences, Inc.
(Name of Issuer)
Common Stock, Par Value $0.00001 per Share
(Title of Class of Securities)
00974H104
(CUSIP Number)
June 12, 2023
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act.
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
aMoon Growth Fund II, L.P.
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Cayman Islands
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
2,500,000
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
2,500,000
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,500,000
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
5.16%(1)
|
|
12.
|
Type of Reporting Person (See Instructions)
PN
|
(1)
|
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus
Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Page 2 of 19 Pages
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
aMoon Growth Fund II G.P., L.P.
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Cayman Islands
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
2,500,000
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
2,500,000
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,500,000
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
5.16%(1)
|
|
12.
|
Type of Reporting Person (See Instructions)
PN
|
(1)
|
(Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities
and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Page 3 of 19 Pages
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
aMoon Growth II General Partner Ltd.
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Israel
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
2,500,000
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
2,500,000
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,500,000
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
5.16%(1)
|
|
12.
|
Type of Reporting Person (See Instructions)
CO
|
(1)
|
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and
Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Page 4 of 19 Pages
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
aMoon Edge Limited Partnership
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Cayman Islands
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
418,439
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
418,439
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
418,439
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
0.86% (1)
|
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and
Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Page 5 of 19 Pages
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
aMoon Edge GP Ltd.
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Cayman Islands
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
418,439
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
418,439
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
418,439
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
0.86% (1)
|
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and
Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Page 6 of 19 Pages
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
Hilliyon Holdings Ltd.
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Israel
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
418,439
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
418,439
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
418,439
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
0.86% (1)
|
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and
Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Page 7 of 19 Pages
<
div style="line-height: 1.25">
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
Berko Capital Ltd.
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Israel
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
418,439
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
418,439
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
418,439
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
0.86% (1)
|
|
12.
|
Type of Reporting Person (See Instructions)
|
(1)
|
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and
Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Page 8 of 19 Pages
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
Dr. Yair C. Schindel
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Israel
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
2,918,439
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
2,918,439
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,918,439
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
6.03% (1)
|
|
12.
|
Type of Reporting Person (See Instructions)
IN
|
(1)
|
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and
Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Page 9 of 19 Pages
CUSIP No.
|
00974H104
|
|
1.
|
Names of Reporting Persons
Dr. Tomer Berkovitz
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions)
(a) ☑
(b) ☐
|
|
3.
|
SEC Use Only
|
|
4.
|
Citizenship or Place of Organization
Israel
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5.
|
Sole Voting Power
0
|
6.
|
Shared Voting Power
418,439
|
|
7.
|
Sole Dispositive Power
0
|
|
8.
|
Shared Dispositive Power
418,439
|
|
9.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
418,439
|
|
10.
|
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
☐
|
|
11.
|
Percent of Class Represented by Amount in Row (9)
0.86% (1)
|
|
12.
|
Type of Reporting Person (See Instructions)
IN
|
(1)
|
Based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the Issuer’s Prospectus Supplement filed with the U.S. Securities and
Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
|
Item 1(a) Name of Issuer
Akoya Biosciences, Inc. (the “Issuer”).
|
Item 1(b) Address of Issuer’s Principal Executive Offices
100 Campus Drive, 6th Floor, Marlborough, MA 01752.
|
Item 2(a)-(b) Name of Person Filing; Address of Principal Business Office or, if none, Residence
1. |
aMoon Growth Fund II, L.P. (“aMoon”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
2. |
aMoon Growth Fund II G.P., L.P. (“aMoon G.P.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
3. |
aMoon Growth II General Partner Ltd., (“aMoon Ltd.”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
4. |
aMoon Edge Limited Partnership (“aMoon Edge”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
5. |
aMoon Edge GP Ltd., (“aMoon Edge Ltd.”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
6. |
Hilliyon Holdings Ltd., (“Hilliyon”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
7. |
Berko Capital Ltd., an Israeli company (“Berko Capital”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
8. |
Dr. Yair C. Schindel (“Schindel”), 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
9. |
Dr. Tomer Berkovitz (“Berkovitz”) 34 Yerushalaim Rd, Beit Gamla, 6th Floor, Ra’anana, 4350110, Israel.
|
The foregoing persons are hereinafter collectively referred to as the “Reporting Persons”.
|
Item 2(c) Citizenship
aMoon is a Cayman Islands exempted limited partnership; aMoon G.P. is a Cayman Islands exempted limited partnership; aMoon Ltd. is an Israeli
company; aMoon Edge is a Cayman Islands exempted limited partnership; aMoon Edge Ltd. is a Cayman Islands company; Hilliyon is an Israeli company; Berko Capital is an Israeli company;
Schindel is an Israeli citizen and Berkovitz is an Israeli citizen.
|
Page 11 of 19
Pages
Item 2(d) Title of Class of Securities
Common Stock, par value $0.00001 per share
|
Item 2(e) CUSIP Number
00974H104
|
Item 3 |
If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
|
Not applicable.
|
Item 4 Ownership
All share percentage calculation below are based on 48,404,071 shares of Common Stock issued and outstanding, as reported in the
Issuer’s Prospectus Supplement filed with the U.S. Securities and Exchange Committee pursuant to Rule 424(b)(5) on June 9, 2023.
aMoon
Growth Fund II, L.P.
|
(a) |
Amount beneficially owned: 2,500,000 shares of Common Stock.
|
(b) |
Percent of Class: 5.16%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 2,500,000 shares of Common Stock
|
aMoon Growth Fund II G.P., L.P.
|
(a) |
Amount beneficially owned: 2,500,000 shares of Common Stock.
|
(b) |
Percent of Class: 5.16%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 2,500,000 shares of Common Stock.
|
Page 12 of 19
Pages
aMoon Growth II General Partner Ltd.
|
(a) |
Amount beneficially owned: 2,500,000 shares of Common Stock.
|
(b) |
Percent of Class: 5.16%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 2,500,000 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 2,500,000 shares of Common Stock.
|
aMoon Edge Limited Partnership
|
(a) |
Amount beneficially owned: 418,439 shares of Common Stock.
|
(b) |
Percent of Class: 0.86%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 418,439 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.
|
aMoon Edge GP Ltd.
|
(a) |
Amount beneficially owned: 418,439 shares of Common Stock.
|
(b) |
Percent of Class: 0.86%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 418,439 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.
|
Hilliyon Holdings Ltd.
|
(a) |
Amount beneficially owned: 418,439 shares of Common Stock.
|
(b) |
Percent of Class: 0.86%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 418,439 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.
|
Page 13 of
19 Pages
Berko Capital Ltd.
|
(a) |
Amount beneficially owned: 418,439 shares of Common Stock.
|
(b) |
Percent of Class: 0.86%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 418,439 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock.
|
Dr. Yair C. Schindel
|
(a) |
Amount beneficially owned: 2,918,439 shares of Common Stock. (i) Schindel is the sole shareholder of aMoon Ltd. By virtue of such relationships, Schindel may be deemed to share voting and investment
power with respect to the shares of Common Stock of the Issuer held by aMoon; (ii) aMoon Edge Ltd. is the sole general partner of aMoon Edge pursuant to the terms of the limited partnership agreement
of aMoon Edge. Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd. and Schindel is the sole shareholder of Hilliyon. By virtue of such relationships, Schindel may be deemed to share
voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Schindel disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon, aMoon G.P. aMoon Ltd., aMoon
Edge, aMoon Edge Ltd., and Hilliyon, except to the extent of his pecuniary interest therein, if any.
|
(b) |
Percent of Class: 6.03%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 2,918,439 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 2,918,439 shares of Common Stock.
|
Dr. Tomer Berkovitz
|
(a) |
Amount beneficially owned: 418,439 shares of Common Stock. Hilliyon and Berko Capital are the sole shareholders of aMoon Edge Ltd., and Berkovitz is the sole shareholder of Berko Capital. By virtue of such relationships, Berkovitz may be deemed to share voting and investment power with respect to the shares of Common Stock of the Issuer held by aMoon Edge. Berkovitz disclaims beneficial ownership of the shares of Common Stock of the Issuer held by aMoon Edge, aMoon Edge Ltd. and Berko Capital, except to the extent of his pecuniary interest therein, if any.
|
(b) |
Percent of Class: 0.86%
|
(c) |
Number of shares as to which the person has:
|
(i) |
Sole power to vote or direct the vote: 0
|
(ii) |
Shared power to vote or to direct the vote: 418,439 shares of Common Stock
|
(iii) |
Sole power to dispose or to direct the disposition of: 0
|
(iv) |
Shared power to dispose or to direct the disposition of: 418,439 shares of Common Stock
|
Item 5 |
Ownership of Five Percent or Less of a Class
|
Not applicable.
|
Item 6 |
Ownership of More than Five Percent on Behalf of Another Person
|
Not applicable.
|
Item 7 |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
|
Not applicable.
|
Page 14 of 19 Pages
Item 8 |
Identification and Classification of Members of the Group
|
Incorporated by reference to Items 2 and 4 of this Schedule 13G.
|
Item 9 |
Notice of Dissolution of Group
|
Not applicable.
|
Item 10 |
Certification
|
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not
acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
|
Page 15 of
19 Pages
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: June 13, 2023
AMOON GROWTH FUND II L.P.
BY: AMOON GROWTH FUND II G.P., L.P., ITS GENERAL PARTNER
BY: AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER |
||
By:
|
/s/ Dr. Yair C. Schindel
|
|
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
AMOON GROWTH FUND II G.P., L.P.,
BY: AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
BY: AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
By:
|
/s/ Dr. Yair C. Schindel
|
|
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
AMOON GROWTH II GENERAL PARTNER LTD.
|
||
By:
|
/s/ Dr. Yair C. Schindel
|
|
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
AMOON EDGE LIMITED PARTNERSHIP
BY: AMOON EDGE GP LTD., ITS GENERAL PARTNER |
||
By:
|
/s/ Dr. Yair C. Schindel
|
|
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
Page 16 of 19 Pages
AMOON EDGE GP LTD.
|
||
By:
|
/s/ Dr. Yair C. Schindel
|
|
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
HILLIYON HOLDINGS LTD.
|
||
By:
|
/s/ Dr. Yair C. Schindel
|
|
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
BERKO CAPITAL LTD.
|
||
By:
|
/s/ Dr. Tomer Berkovitz
|
|
|
Name:
Title:
|
Dr. Tomer Berkovitz
Director
|
DR. YAIR C. SCHINDEL
|
|
/s/ Dr. Yair C. Schindel
|
DR. TOMER BERKOVITZ
|
|
/s/ Dr. Tomer Berkovitz
|
Page 17 of 19 Pages
EXHIBIT A TO SCHEDULE 13G
Joint Filing Agreement
The undersigned hereby agree that the Schedule 13G (the “Schedule 13G”), filed by the undersigned with respect to shares of Common Stock, par value $0.00001
per share, of Akoya Biosciences, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and
that this Joint Filing Agreement (this “Agreement”) shall be included as an Exhibit to the Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the
information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement this 13th day of June 2023.
|
AMOON GROWTH FUND II L.P.
BY: AMOON GROWTH FUND II G.P., L.P., ITS GENERAL PARTNER
BY: AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER |
|||
By:
|
/s/ Dr. Yair C. Schindel
|
||
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
AMOON GROWTH FUND II G.P., L.P.,
BY: AMOON GROWTH II GENERAL PARTNER LTD., ITS GENERAL PARTNER
|
|||
By:
|
/s/ Dr. Yair C. Schindel
|
||
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
AMOON GROWTH II GENERAL PARTNER LTD.
|
|||
By:
|
/s/ Dr. Yair C. Schindel
| ||
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
AMOON EDGE LIMITED PARTNERSHIP
BY: AMOON EDGE GP LTD., ITS GENERAL PARTNER |
|||
By:
|
/s/ Dr. Yair C. Schindel
|
||
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
Page 18 of 19
Pages
AMOON EDGE GP LTD.
|
|||
By:
|
/s/ Dr. Yair C. Schindel
|
||
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
HILLIYON HOLDINGS LTD.
|
|||
By:
|
/s/ Dr. Yair C. Schindel
|
||
|
Name:
Title:
|
Dr. Yair C. Schindel
Director
|
BERKO CAPITAL LTD.
|
|||
By:
|
/s/ Dr. Tomer Berkovitz
|
||
|
Name:
Title:
|
Dr. Tomer Berkovitz
Director
|
DR. YAIR C. SCHINDEL
|
|
/s/ Dr. Yair C. Schindel
|
DR. TOMER BERKOVITZ
|
|
/s/ Dr. Tomer Berkovitz
|
Page 19 of 19
Pages